^
Association details:
| Biomarker: | LRP1B deletion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
51 - A phase I/II study of chemo-immunotherapy with durvalumab (durva) and pegylated liposomal doxorubicin (PLD) in platinum-resistant recurrent ovarian cancer (PROC): Genomic sequencing and updated efficacy results
Published date:
03/30/2020
Excerpt:
Deletions of LRP1B were previously shown to drive resistance to PLD. We also found that PFS (P = 0.0016) for patients on PLD + durva negatively correlated with LRP1B deletions.
Secondary therapy:
pegylated liposomal doxorubicin
Trial ID:
